BUY Lupin Limited — ICICI Securities

Entry₹2,391Inferred
Target₹2,418.2
Total upside +1.14% (call closed)
Stop lossNot given
Exit₹2,418.230 Jun 2026, 11:21 am
Target hit+1.14%0.00%upside left

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:50 pm IST
2 supporting0 opposing
Supports the BUY call (2)

2 other SEBI-registered advisors have active intraday BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·30 Jun · today

Lupin Limited received tentative approval from the U.S. FDA for Enzalutamide Tablets on June 26, 2026. This is a step towards potential market approval.

NSE · Press Release·26 Jun · 4d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.